TY - JOUR
T1 - Quantitative PCR detection of t(11;14) bcl-1/JH in mantle cell lymphoma patients
T2 - Comparison of peripheral blood and bone marrow aspirate samples
AU - Di Martino, S.
AU - Catapano, O.
AU - Siesto, S. R.
AU - Di Paolo, M.
AU - Pugliese, S.
AU - Morelli, C. D.
AU - Fiorica, F.
AU - Varriale, E.
AU - Di Francia, R.
AU - Abbadessa, A.
PY - 2015
Y1 - 2015
N2 - OBJECTIVE: Mantle cell lymphoma (MCL) is a non-Hodgkin lymphoma (NHL) featured by participation of the lymph nodes, spleen, blood and bone marrow with a short remission period to standard therapies and a median overall survival of 4-5 years. PATIENTS AND METHODS: In this study, we compare the levels of bcl-1/JH fusion products detected by q-PCR in the concurrent peripheral blood (PB) and bone marrow (BM) aspirate samples from 7 patients with MCL. RESULTS: In patients with moderate to high levels of bcl-1/JH copies, the results of q-PCR analysis of PB and BM aspirate samples correlate well. In patients with high levels of bcl-1/JH copies, instead, PB levels are a good indication of tumor burden. Finally, in patients with low levels of bcl-1/JH copies, the t(11;14) may be detected by identification of neoplastic cells. CONCLUSIONS: Our data suggest that PB can be reliably used in place of BM aspirate both for detection of translocation status during minimal residual disease monitoring and for a possible molecular relapse, especially in those patients who have moderate to high levels of bcl-1/JH copies. If these results will be confirmed on a wider number of MCL patients, future study will be required to address the issue.
AB - OBJECTIVE: Mantle cell lymphoma (MCL) is a non-Hodgkin lymphoma (NHL) featured by participation of the lymph nodes, spleen, blood and bone marrow with a short remission period to standard therapies and a median overall survival of 4-5 years. PATIENTS AND METHODS: In this study, we compare the levels of bcl-1/JH fusion products detected by q-PCR in the concurrent peripheral blood (PB) and bone marrow (BM) aspirate samples from 7 patients with MCL. RESULTS: In patients with moderate to high levels of bcl-1/JH copies, the results of q-PCR analysis of PB and BM aspirate samples correlate well. In patients with high levels of bcl-1/JH copies, instead, PB levels are a good indication of tumor burden. Finally, in patients with low levels of bcl-1/JH copies, the t(11;14) may be detected by identification of neoplastic cells. CONCLUSIONS: Our data suggest that PB can be reliably used in place of BM aspirate both for detection of translocation status during minimal residual disease monitoring and for a possible molecular relapse, especially in those patients who have moderate to high levels of bcl-1/JH copies. If these results will be confirmed on a wider number of MCL patients, future study will be required to address the issue.
KW - BCL1/JH
KW - Disease monitoring
KW - Mantle cell leukaemia
KW - Minimal residual disease
KW - Molecular diagnostics
KW - Quantitative PCR
UR - http://www.scopus.com/inward/record.url?scp=84960917984&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84960917984&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:84960917984
VL - 19
SP - 4801
EP - 4810
JO - European Review for Medical and Pharmacological Sciences
JF - European Review for Medical and Pharmacological Sciences
SN - 1128-3602
IS - 24
ER -